Mersana Therapeutics (Mersana Therapeutics) Market Cap : $356.63 Mil (As of Apr. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Mersana Therapeutics's share price for the quarter that ended in Dec. 2023 was $2.32. Mersana Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 120.71 Mil. Therefore, Mersana Therapeutics's market cap for the quarter that ended in Dec. 2023 was $280.05 Mil.

Mersana Therapeutics's quarterly market cap declined from Jun. 2023 ($396.31 Mil) to Sep. 2023 ($153.10 Mil) but then increased from Sep. 2023 ($153.10 Mil) to Dec. 2023 ($280.05 Mil).

Mersana Therapeutics's annual market cap increased from Dec. 2021 ($458.47 Mil) to Dec. 2022 ($616.15 Mil) but then declined from Dec. 2022 ($616.15 Mil) to Dec. 2023 ($280.05 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Mersana Therapeutics's Enterprise Value for Today is $170.26 Mil.

Mersana Therapeutics Market Cap Historical Data

The historical data trend for Mersana Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Market Cap Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

260.07

1,831.87

458.47

616.15

280.05

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															616.15	448.24	396.31	153.10	280.05

Competitive Comparison of Mersana Therapeutics's Market Cap

For the Biotechnology subindustry, Mersana Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Market Cap falls into.

Mersana Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Mersana Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$2.32	*	120.712
	=	$280.05

Mersana Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$2.32	*	120.712
	=	$280.05

Mersana Therapeutics (NAS:MRSN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Mersana Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (Mersana Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Executives

Anna Protopapas	director, officer: President and CEO	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala	officer: SVP, Chief Development Officer	C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tushar Misra	officer: Chief Manufacturing Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner	officer: Sr. VP, Finance & Product stgy	840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia	officer: VP, Controller	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger	officer: Chief Scientific Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang	officer: Chief Medical Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman	officer: Sr VP Chmistry, Man & Control	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack	officer: CBO, Treasurer & Secretary	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Scott D Sandell	10 percent owner